Loading...
XJPX
4556
Market cap34mUSD
Dec 05, Last price  
1,270.00JPY
1D
0.71%
1Q
-0.39%
Jan 2017
106.50%
Name

Kainos Laboratories Inc

Chart & Performance

D1W1MN
XJPX:4556 chart
P/E
8.27
P/S
1.00
EPS
153.57
Div Yield, %
2.52%
Shrs. gr., 5y
0.53%
Rev. gr., 5y
2.85%
Revenues
5.31b
+4.93%
4,609,421,0004,257,858,0004,614,725,0004,923,245,0005,056,463,0005,305,569,000
Net income
641m
+0.48%
398,572,000417,405,000512,334,000568,174,000637,965,000641,019,000
CFO
705m
+63.68%
678,181,000591,249,000604,363,000544,510,000430,578,000704,782,000
Dividend
Mar 30, 202632 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.
IPO date
Dec 04, 1995
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT